title: 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
abstract: OBJECTIVE
  This analysis examines the relative effectiveness of current medical therapies for BPH in preventing AUR, AUR-related catheterisation and surgery in real-life clinical practice.
  
  
  METHODS
  This is a retrospective analysis of observational data from the General Practice Research Database (UK) (GPRD). The cohort contains 4500 patients experiencing BPH or lower urinary tract symptoms strongly suggestive of BPH, aged over 50 years, who were prescribed a 5ARI (finasteride) or an alpha-blocker (alfuzosin, doxazosin, indoramin, prazosin, tamsulosin, terazosin) as their first BPH treatment between 1996 and 1999 inclusive. Cox regression and competing risks analyses, adjusted for age and year of first treatment, followed patients from the start of their first BPH treatment to AUR, catheterisation or surgery, or censoring.
  
  
  RESULTS
  Patients prescribed an alpha-blocker were significantly more likely to experience AUR (hazard ratio 2.32, 95%CI 1.37, 3.94) or surgery (hazard ratio 1.78, 95%CI 1.30, 2.44) than patients prescribed a 5ARI. These differences were sustained with sensitivity analyses.
  
  
  CONCLUSIONS
  Real-life clinical practice shows that significantly fewer BPH patients prescribed a 5ARI experienced serious complications associated with the progression of BPH compared with those prescribed an alpha-blocker.
authors.affiliation: Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. director@iarc.fr
authors.forename: P
authors.initials: P
authors.lastname: Boyle
authors.forename: C
authors.initials: C
authors.lastname: Roehrborn
authors.forename: R
authors.initials: R
authors.lastname: Harkaway
authors.forename: J
authors.initials: J
authors.lastname: Logie
authors.forename: J
authors.initials: J
authors.lastname: de la Rosette
authors.forename: M
authors.initials: M
authors.lastname: Emberton
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000208:Acute Disease; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy* / Q000601:surgery; D012044:Regression Analysis; D012189:Retrospective Studies; D016055:Urinary Retention / Q000209:etiology / Q000517:prevention & control*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride